Search

C18H19N5, triclinic, P1‾ $P\overline{1}$ (no. 2), a = 6.612(4) Å, b = 8.800(5) Å, c = 13.777(8) Å, α = 83.219(7)°, β = 79.329(6)°, γ = 78.744(6)°, V = 769.8(8) Å3, Z = 2, R gt(F) = 0.0394, wR ref(F 2) = 0.0996, T = 100(2) K.

Zn2C8H32N4O16S4${\text{Zn}}_{2}{\text{C}}_{8}{\text{H}}_{32}{\text{N}}_{4}{\text{O}}_{16}{\text{S}}_{4}$, triclinic, P1‾$P‾{1}$ (no. 2), a = 9.0313(9) Å, b = 9.6075(14) Å, c = 15.3044(15) Å, α = 89.933(2)°, β = 78.579(1)°, γ = 68.878(1)°, V = 1210.6(2) Å3, Z = 2, Rgt${R}_{gt}$(F) = 0.0323, wRref$w{R}_{\mathit{ref}}$(F2) = 0.1043, T = 100(2) K.

For instance, by employing a tripodal bis(benzimidazole) ligand bis((1-methylbenzimidazol-2-yl)methyl)amine(MeIDB) and its derivative as the main ligand, a series of nickel and copper complexes were synthesized which allow a systematic investigation of a biomimetic chemistry [[8]]. Comment Multi-benzimidazole ligands have been often used in the synthesis of various metal-organic complexes or modelling the biomimetic coordination environment around the enzymatic active site [[7]]. However, up to now the detailed crystallization properties of MeIDB has been not reported which can be helpful for the design of various multifunctional compounds due to its central acyclic -CH SB 2 sb -N-CH SB 2 sb - linkage moiety, making the ligand possess various steric arrangements. [Extracted from the article]

For instance, by employing a tripodal bis(benzimidazole) ligand bis((1-methylbenzimidazol-2-yl)methyl)amine(MeIDB) and its derivative as the main ligand, a series of nickel and copper complexes were synthesized which allow a systematic investigation of a biomimetic chemistry [[8]]. Comment Multi-benzimidazole ligands have been often used in the synthesis of various metal-organic complexes or modelling the biomimetic coordination environment around the enzymatic active site [[7]]. However, up to now the detailed crystallization properties of MeIDB has been not reported which can be helpful for the design of various multifunctional compounds due to its central acyclic -CH SB 2 sb -N-CH SB 2 sb - linkage moiety, making the ligand possess various steric arrangements. [Extracted from the article]

Zn2C8H32N4O16S4, triclinic, P1 (no. 2), a = 9.0313(9) Å, b = 9.6075(14) Å, c = 15.3044(15) Å, α = 89.933(2)°, β = 78.579(1)°, γ = 68.878(1)°, V = 1210.6(2) Å3, Z = 2, Rgt (F) = 0.0323, wRref (F2) = 0.1043, T = 100(2) K. [ABSTRACT FROM AUTHOR]

C15H13N5O9Zn2, monoclinic, P21/n (no. 14), a = 6.7739(13) Å, b = 14.160(3) Å, c = 18.506(4) Å, β = 97.908(4)°, V = 1758.1(6) Å3, Z = 4, Rgt(F) = 0.0597, wRref(F2) = 0.1125, T = 298(2) K. [ABSTRACT FROM AUTHOR]

Zn2C8H32N4O16S4, triclinic, P1 (no. 2), a = 9.0313(9) Å, b = 9.6075(14) Å, c = 15.3044(15) Å, α = 89.933(2)°, β = 78.579(1)°, γ = 68.878(1)°, V = 1210.6(2) Å3, Z = 2, Rgt (F) = 0.0323, wRref (F2) = 0.1043, T = 100(2) K. [ABSTRACT FROM AUTHOR]